Cargando…

Androgen receptor profiling predicts prostate cancer outcome

Prostate cancer is the second most prevalent malignancy in men. Biomarkers for outcome prediction are urgently needed, so that high-risk patients could be monitored more closely postoperatively. To identify prognostic markers and to determine causal players in prostate cancer progression, we assesse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stelloo, Suzan, Nevedomskaya, Ekaterina, van der Poel, Henk G, de Jong, Jeroen, van Leenders, Geert JLH, Jenster, Guido, Wessels, Lodewyk FA, Bergman, Andries M, Zwart, Wilbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644377/ https://www.ncbi.nlm.nih.gov/pubmed/26412853 http://dx.doi.org/10.15252/emmm.201505424

Ejemplares similares

Androgen receptor DNA binding and chromatin accessibility profiling in prostate cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2015)

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma
por: Stelloo, Suzan, et al.
Publicado: (2016)

Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration
por: Cioni, Bianca, et al.
Publicado: (2018)

Optimized ChIP-seq method facilitates transcription factor profiling in human tumors
por: Singh, Abhishek A, et al.
Publicado: (2018)

Genome-wide epigenetic profiling of breast cancer tumors treated with aromatase inhibitors
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2014)

Integrative epigenetic taxonomy of primary prostate cancer
por: Stelloo, Suzan, et al.
Publicado: (2018)

TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
por: Palit, Sander AL, et al.
Publicado: (2019)

Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
por: Linder, Simon, et al.
Publicado: (2018)

Gene-expression analysis of gleason grade 3 tumor glands embedded in low- and high-risk prostate cancer
por: Hoogland, A. Marije, et al.
Publicado: (2016)

The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics
por: Siefert, Joseph C., et al.
Publicado: (2021)

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion
por: Cioni, Bianca, et al.
Publicado: (2020)

Functional mapping of androgen receptor enhancer activity
por: Huang, Chia-Chi Flora, et al.
Publicado: (2021)

Novel long non-coding RNAs are specific diagnostic and prognostic markers for prostate cancer
por: Böttcher, René, et al.
Publicado: (2015)

Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases
por: Böttcher, René, et al.
Publicado: (2016)

Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer
por: Kolijn, Kimberley, et al.
Publicado: (2015)

The Effects of Enzalutamide Monotherapy on Multiparametric 3T MR Imaging in Prostate Cancer
por: Van der Roest, Rosanne CV., et al.
Publicado: (2016)

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer
por: Severson, Tesa, et al.
Publicado: (2022)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
por: van der Zande, Kim, et al.
Publicado: (2021)

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential
por: Kneppers, Jeroen, et al.
Publicado: (2022)

Non-prostatic pathology on prostate needle-biopsy – colorectal carcinoid: a case report
por: van den Bergh, Roderick CN, et al.
Publicado: (2009)

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model
por: Passier, Margot, et al.
Publicado: (2023)

Epigenetic and transcriptional analysis reveals a core transcriptional program conserved in clonal prostate cancer metastases
por: Severson, Tesa M., et al.
Publicado: (2021)

Bypass Mechanisms of the Androgen Receptor Pathway in Therapy-Resistant Prostate Cancer Cell Models
por: Marques, Rute B., et al.
Publicado: (2010)

Reduced NCOR2 expression accelerates androgen deprivation therapy failure in prostate cancer
por: Long, Mark D., et al.
Publicado: (2021)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
por: Van Hemelryk, Annelies, et al.
Publicado: (2022)

A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer
por: Palit, Sander A. L., et al.
Publicado: (2021)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Modulation of Androgen Receptor Signaling in Hormonal Therapy-Resistant Prostate Cancer Cell Lines
por: Marques, Rute B., et al.
Publicado: (2011)

Tissue proteomics outlines AGR2 AND LOX5 as markers for biochemical recurrence of prostate cancer
por: Rodríguez-Blanco, Giovanny, et al.
Publicado: (2018)

Updating the Rotterdam Prostate Cancer Risk Calculator with Invasive Cribriform and/or Intraductal Carcinoma for Men with a Prior Negative Biopsy
por: Remmers, Sebastiaan, et al.
Publicado: (2021)

PD-L1 expression in urothelial bladder cancer varies more among specimen types than between companion assays
por: de Jong, Joep J., et al.
Publicado: (2021)

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo
por: Kim, Yongsoo, et al.
Publicado: (2019)

Neoadjuvant tamoxifen synchronizes ERα binding and gene expression profiles related to outcome and proliferation
por: Severson, Tesa M., et al.
Publicado: (2016)

Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
por: Osses, Daniël F., et al.
Publicado: (2020)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis
por: Hollemans, Eva, et al.
Publicado: (2018)

Activation of c-MET Induces a Stem-Like Phenotype in Human Prostate Cancer
por: van Leenders, Geert J. L. H., et al.
Publicado: (2011)

From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2022)

Differential tissue expression of extracellular vesicle‐derived proteins in prostate cancer
por: Duijvesz, Diederick, et al.
Publicado: (2019)

The adaptive immune system promotes initiation of prostate carcinogenesis in a human c-Myc transgenic mouse model
por: Melis, Monique H.M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n5eggtomq64ec5i486k1bisfl6